Novel human coronavirus infection: Difference between revisions
No edit summary |
No edit summary |
||
Line 14: | Line 14: | ||
{{SK}} Human betacoronavirus 2c EMC/2012; novel coronavirus | {{SK}} Human betacoronavirus 2c EMC/2012; novel coronavirus | ||
==[[Novel human coronavirus infection overview|Overview]]== | |||
==[[Novel human coronavirus infection historical perspective|Historical Perspective]]== | |||
==[[Novel human coronavirus infection classification|Classification]]== | |||
==[[Novel human coronavirus infection pathophysiology|Pathophysiology]]== | |||
==[[Novel human coronavirus infection causes|Causes]]== | |||
==[[Novel human coronavirus infection differential diagnosis|Differentiating Novel Human Coronavirus Infection from other Diseases]]== | |||
==[[Novel human coronavirus infection epidemiology and demographics|Epidemiology and Demographics]]== | |||
==[[Novel human coronavirus infection risk factors|Risk Factors]]== | |||
==[[Novel human coronavirus infection natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | |||
==Diagnosis== | |||
[[Novel human coronavirus infection history and symptoms|History and Symptoms]] | [[Novel human coronavirus infection physical examination|Physical Examination]] | [[Novel human coronavirus infection laboratory findings|Laboratory Findings]] | [[[[Novel human coronavirus infection chest x ray | |||
|Chest X Ray]] | [[Novel human coronavirus infection other imaging findings|Other Imaging Findings]] | [[Novel human coronavirus infection other diagnostic studies|Other Diagnostic Studies]] | |||
==Treatment== | |||
[[Novel human coronavirus infection medical therapy|Medical Therapy]] | [[Novel human coronavirus infection primary prevention|Primary Prevention]] | [[Novel human coronavirus infection secondary prevention|Secondary Prevention]] | [[Novel human coronavirus infection cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Novel human coronavirus infection future or investigational therapies|Future or Investigational Therapies]] | |||
==Case Studies== | |||
[[Novel human coronavirus infection case study one|Case #1]] | |||
==External Links== | ==External Links== |
Revision as of 20:11, 1 January 2013
Coronavirus | ||||||||
---|---|---|---|---|---|---|---|---|
Virus classification | ||||||||
|
Novel Human Coronavirus Infection Microchapters |
Differentiating Novel Human Coronavirus Infection from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Novel human coronavirus infection On the Web |
American Roentgen Ray Society Images of Novel human coronavirus infection |
Directions to Hospitals Treating Novel human coronavirus infection |
Risk calculators and risk factors for Novel human coronavirus infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Synonyms and keywords: Human betacoronavirus 2c EMC/2012; novel coronavirus
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | [[[[Novel human coronavirus infection chest x ray |Chest X Ray]] | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies